Company Overview
Snapshot
Founded in February 2016 by Fuad Fares and Lital Sharvit, CanCuRX operates with 1–10 employees. The company has secured one funding round and holds patents for its mushroom-derived compound and treatment process, indicating a strong focus on intellectual property in its preclinical development.
Business overview
CanCuRX is a preclinical-stage biopharmaceutical company dedicated to improving survival rates for pancreatic cancer patients. The company develops a novel treatment based on a mushroom-derived compound that inhibits pancreatic cell growth. Working in collaboration with the Carmel Innovations Fund of the University of Haifa, CanCuRX operates within the Health Tech & Life Sciences sector, specifically focusing on Pharmaceuticals and Diagnostics, with a core technology in biologicals and herbals.
Strategic signal
In January 2019, a news article highlighted Fuad Fares, a co-founder of CanCuRX, as a Druze hi-tech pioneer. This recognition signals the company's foundational leadership and its potential to contribute to the biopharmaceutical landscape through innovative research and development in cancer therapy.
Log in to access full profile ›Company Intelligence Q&A
- When was CanCuRX founded?
- CanCuRX was founded in February 2016.
- Who are the founders of CanCuRX?
- CanCuRX was founded by Fuad Fares and Lital Sharvit.
- What is CanCuRX's primary focus?
- CanCuRX is a preclinical-stage biopharmaceutical company focused on developing a novel treatment for pancreatic cancer using a mushroom-derived compound.
- Does CanCuRX hold any patents?
- Yes, CanCuRX holds patents registered for its mushroom strain, the extract prepared from it, and the treatment process.
- What is the company's stage of development?
- CanCuRX is currently in the R&D product stage, with its funding stage classified as Seed and public stage as Pre-Funding.